{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:41:41Z","timestamp":1777261301364,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.aed.2025.11.001","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:53:46Z","timestamp":1763348026000},"page":"303-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevention and Management of Peptide Receptor Radionuclide Therapy-Induced Hypertensive Crisis in a Patient With Metastatic Pheochromocytoma"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-5102","authenticated-orcid":false,"given":"Run","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Salavati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadfar","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.aed.2025.11.001_bib1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.eprac.2023.07.027","article-title":"Diagnosis and management of pheochromocytomas and paragangliomas: a guide for the clinician","volume":"29","author":"Sharma","year":"2023","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.aed.2025.11.001_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.amjmed.2008.08.021","article-title":"Diagnosis and treatment of pheochromocytoma in an academic hospital from 1997 to 2007","volume":"122","author":"Yu","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.aed.2025.11.001_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2024.101116","article-title":"Management of metastatic pheochromocytomas and paragangliomas: when and what","volume":"51","author":"Sukrithan","year":"2024","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"10.1016\/j.aed.2025.11.001_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000499497","article-title":"Peptide receptor radionuclide therapy as a novel treatment for metastatic and invasive phaeochromocytoma and paraganglioma","volume":"109","author":"Mak","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.aed.2025.11.001_bib5","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/jcm9072203","article-title":"Prevention and management of hormonal crisis during theragnosis with LU-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal","volume":"9","author":"Del Olmo-Garc\u00eda","year":"2020","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.aed.2025.11.001_bib6","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.aed.2025.11.001_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.aed.2025.11.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100171","article-title":"Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials","volume":"6","author":"Severi","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.aed.2025.11.001_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13349","article-title":"Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: a single-institution experience and review of the literature","volume":"35","author":"Tang","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"10.1016\/j.aed.2025.11.001_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate","volume":"35","author":"de Keizer","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.aed.2025.11.001_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","article-title":"The challenges of treating paraganglioma patients with (177)Lu-DOTATATE PRRT: catecholamine crises, tumor lysis syndrome and the need for modification of treatment protocols","volume":"49","author":"Makis","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.aed.2025.11.001_bib12","doi-asserted-by":"crossref","DOI":"10.1507\/endocrj.EJ24-0713","article-title":"Potentially fatal crisis after 177Lu-DOTATATE therapy for paraganglioma: a case report with review of literature","author":"Tobimatsu","year":"2025","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.aed.2025.11.001_bib13","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Preoperative management of the pheochromocytoma patient","volume":"92","author":"Pacak","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.aed.2025.11.001_bib14","doi-asserted-by":"crossref","first-page":"e2393","DOI":"10.1210\/clinem\/dgab130","article-title":"The role for metyrosine in the treatment of patients with pheochromocytoma and paraganglioma","volume":"106","author":"Gruber","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725001560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725001560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:30:16Z","timestamp":1777260616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915725001560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3050915725001560"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2025.11.001","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and Management of Peptide Receptor Radionuclide Therapy-Induced Hypertensive Crisis in a Patient With Metastatic Pheochromocytoma","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2025.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Association of Clinical Endocrinology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}